Compare Moderna, Inc. (MRNA) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs S&P Global Inc — how do they compare? Moderna, Inc. trades at $60.76 (market cap $23.88B), while S&P Global Inc trades at $408.3 (market cap $121.15B). The key difference: S&P Global Inc is far larger — about 5.1× Moderna, Inc.'s market cap, and S&P Global Inc pays a 0.94% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SPGI | |
|---|---|---|
Market Cap | $23.88B | $121.15B |
Sector | Health | Financials |
52-Week High | $81.80 | $534.79 |
52-Week Low | $22.36 | $370.42 |
Enterprise Value | $20.03B | $132.63B |
Dividend Yield | — | 0.94% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
